Glimicure M 2mg/500mg Tablet is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, acts by stimulating pancreatic beta cells to release insulin, thereby enhancing insulin secretion and reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production, improves insulin sensitivity, and enhances peripheral glucose uptake and utilization. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately controlled by diet, exercise, or monotherapy. Glimicure M is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and exercise. It is important to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Common side effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and, less commonly, hypoglycemia. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Glimicure M should be used under medical supervision with periodic assessment of renal function and blood glucose to ensure safety and efficacy.